Central Oncology Review
Advarra meets the growing needs of oncology by offering robust human subject protections that cancer research institutions expect.
Advarra meets the growing needs of oncology by offering robust human subject protections that cancer research institutions expect.
In the complex landscape of clinical trials, the data monitoring committee (DMC) serves as the cornerstone at the intersection of
Simplify study startup with an IRB reliance agreement that defines roles, ensures compliance, and prepares your institution for streamlined oversight.
Join the Gene Therapy Network to accelerate study activation, gain IBC support, and position your site as a preferred choice for sponsors.
Advarra’s biosafety experts streamline startup for gene therapy trials with comprehensive IBC reviews and proven rapid turnaround times.
In an era where clinical trials are increasingly global, it’s more imperative than ever to leverage international expertise. Data and
Comprehensive IBC submissions require detailed materials, including investigator CVs, safety protocols, and site-specific SOPs for study agent handling.
The revised Common Rule introduces new exemptions, refined consent elements, and alters IRB oversight for multisite and minimal-risk research.
Navigate federal grant applications with Advarra’s expert checklist. Our streamlined process ensures compliance and participant protections for your research.
Advarra’s institutional review board (IRB) strives to protect participant rights and welfare throughout the research process.
DMC services Data monitoring committee (DMC) Independent DMC oversight supported by a 1500+ expert member network Advarra DMC services provide
More than four decades of ethical review leadership Advarra is the largest central IRB, pairing scale with deep scientific, regulatory,